Dodi Protero

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Poster, Conference, Ensitrelvir, Enzyme assay, Viral, Novel, Pan, SARS-CoV-2, Arbutus, International Conference on Emerging Infectious Diseases, Gesellschaft mit beschränkter Haftung, ICAR, Dodi Protero, Virology, Antiviral Research, EC50, Omicron, Therapy, IND, Pharmaceutical industry, Vaccine, Mpro

WARMINSTER, Pa., March 14, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that preclinical data for AB-343, our novel oral SARS-CoV-2 Mpro inhibitor, has been presented in poster format at the 36th International Conference on Antiviral Research (ICAR), in Lyon, France.

Key Points: 
  • “We are excited that our preclinical data for AB-343 has been selected for poster presentation at ICAR.
  • Many of the studies compared AB-343 to nirmatrelvir, the active ingredient in Pfizer’s Paxlovid™ and ensitrelvir, the active ingredient in Shionogi’s Xocova®.
  • The results showed that AB-343 targets SARS-CoV-2 Mpro and inhibits viral replication in vitro (EC50 ~ 20nM).
  • Some of these studies were conducted in part with Proteros biostructures GmbH under the discovery research and license agreement entered into in April 2021.

Proteros receives minority investment from private equity firm Inflexion

Retrieved on: 
Monday, January 9, 2023
Gesellschaft mit beschränkter Haftung, Negotiation, Biotechnology, Development, Partnership, Strategic business unit, Marketing, Growth, LLP, Mylab Discovery Solutions, Financial services, Cryptocurrency, Protein, Pharma, Dodi Protero, Inflection

MARTINSRIED, Germany and MUNICH, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.

Key Points: 
  • MARTINSRIED, Germany and MUNICH, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.
  • Inflexion is a leading mid-market private equity firm which works in partnership with ambitious management teams of high growth, entrepreneurial businesses to accelerate sustainable growth.
  • Funds advised by Inflexion Private Equity Partners LLP have funds under management of c.£7.1bn.
  • Dr. Torsten Neuefeind, founder and CEO of Proteros, said: “I am excited to have Inflexion on board as a partner.

EQS-News: Proteros receives minority investment from private equity firm Inflexion

Retrieved on: 
Sunday, January 22, 2023
Marketing, Partnership, Gesellschaft mit beschränkter Haftung, Growth, Mylab Discovery Solutions, LLP, Development, Strategic business unit, Negotiation, Biotechnology, Security (finance), Financial services, Cryptocurrency, Inflection, Dodi Protero, Protein, Pharma

Martinsried/Munich, Germany – January 9, 2023 – Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.

Key Points: 
  • Martinsried/Munich, Germany – January 9, 2023 – Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.
  • Inflexion is a leading mid-market private equity firm which works in partnership with ambitious management teams of high growth, entrepreneurial businesses to accelerate sustainable growth.
  • Funds advised by Inflexion Private Equity Partners LLP have funds under management of c.£7.1bn.
  • Dr. Torsten Neuefeind, founder and CEO of Proteros, said: "I am excited to have Inflexion on board as a partner.

EQS-News: Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Friday, October 28, 2022
Diamond, Drug discovery, Max Planck Society, Drug development, Villigen, Disease, Gesellschaft mit beschränkter Haftung, Drug design, Probability, GSK, Olaparib, Lists of diseases, Max Planck Institute of Biochemistry, Joint Planning and Development Office, Biology, Science, University College London, Cancer, Gene, Nobel Prize, Genome, Partnership, Pharmaceutical industry, IND, Dodi Protero

Martinsried/Munich, Germany October 25, 2022 Proteros biostructures GmbH (Proteros) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases.

Key Points: 
  • Martinsried/Munich, Germany October 25, 2022 Proteros biostructures GmbH (Proteros) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases.
  • Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.
  • The partners will jointly discover lead compounds with the goal of further developing them into first-in-class drugs for intractable genetic diseases.
  • Adrestias carefully validated targets, discovered through their unique platform, and their broad potential in disease applications are an inspiration to Proteros.

Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Tuesday, October 25, 2022
Diamond, Lists of diseases, Drug design, GSK, Disease, Science, Nobel Prize, Max Planck Institute of Biochemistry, Drug development, Biology, Villigen, Joint Planning and Development Office, Partnership, Olaparib, Max Planck Society, Probability, University College London, Drug discovery, Gesellschaft mit beschränkter Haftung, GLOBE, Genome, Gene, Cancer, Pharmaceutical industry, IND, Dodi Protero

Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.

Key Points: 
  • Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.
  • The partners will jointly discover lead compounds with the goal of further developing them into first-in-class drugs for intractable genetic diseases.
  • Adrestias carefully validated targets, discovered through their unique platform, and their broad potential in disease applications are an inspiration to Proteros.
  • We are delighted to support Adrestia in their accelerated drug discovery endeavors for a variety of complex targets to treat genetic diseases, said Dr. Debora Konz Makino, Proteros VP Business Unit Discovery Solutions.

Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Tuesday, October 25, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Diamond, Lists of diseases, Master of Science, Drug design, Diamond Light Source, University of Nottingham, GSK, Therapy, Disease, Hope, Science, Amphisbaena, Nobel Prize, University, Max Planck Institute of Biochemistry, Drug development, Research, Joint Planning and Development Office, Villigen, Astex, Institute, Partnership, Olaparib, Artificial intelligence, Cancer, Gene, Max Planck Society, Probability, University College London, Drug discovery, Atlas, Doctor of Philosophy, Industry, Charles River Laboratories, Gesellschaft mit beschränkter Haftung, Cancer Research UK, Genetics, Genome, Head, GW Pharmaceuticals, Pharmaceutical industry, IND, Chemistry, Dodi Protero, Adrasteia

Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.

Key Points: 
  • Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.
  • He has led or been involved with the delivery of seven drug candidates across a range of target classes.
  • In Jamess most recent position he ran the medicinal chemistry function at Amphista Therapeutics.
  • Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new targets for treating intractable genetic diseases.

Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca

Retrieved on: 
Monday, May 16, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Research, Gesellschaft mit beschränkter Haftung, Microscopy, Cancer, Drug discovery, USD, AstraZeneca, CEO, Pharmaceutical industry, Dodi Protero

Proteros biostructures GmbH (Proteros), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs.

Key Points: 
  • Proteros biostructures GmbH (Proteros), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs.
  • The new multi-year agreement builds on an ongoing collaboration with AstraZeneca announced in June 2021, to include the development of small molecule inhibitors targeting a second cancer-associated epigenetic protein.
  • The collaboration combines Proteros expertise in the identification and characterization of inhibitors with novel binding mechanisms for technically challenging drug targets with AstraZenecas leadership in the discovery and development of oncology medicines.
  • The expansion of our agreement with AstraZeneca with an additional drug discovery program reflects our successful ongoing collaboration to identify selective inhibitors for notoriously challenging disease targets, said Dr. Torsten Neuefeind, CEO of Proteros.

Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 5, 2021
Company, Clinical trial, Research, Investment, Dodi Protero, Coronavirus, Na, Food, Arbutus, CTA, IND, Gesellschaft mit beschränkter Haftung, COVID-19, World, European Association for the Study of the Liver, Drug discovery, Membrane protein, Assembly, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Travel, World Health Organization, Hospital, Safety, Therapy, HBV, Pharmaceutical industry, Vaccine, Tutoring

This clinical trial is expected to initiate in the second half of 2021.

Key Points: 
  • This clinical trial is expected to initiate in the second half of 2021.
  • We expect to file a Clinical Trial Application(CTA) in the second half of 2021 and initiate the clinical trial in early 2022.
  • Arbutus completed CTA/IND-enabling studies in the fourth quarter of 2020 and initiated a Phase 1a/1b clinical trial for AB-836 in the first quarter of 2021.
  • Initial data from healthy volunteers and HBV subjects from this clinical trial is expected in second half of 2021.